Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Jan 11;11(1):80. doi: 10.3390/cancers11010080

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Results of the adjuvant therapy for curatively resected gastric cancer random effects network meta-analysis (NMA-2) for 14 different treatment modalities in terms of disease free survival. Relative effects in combined hazard ratios and 95% credible intervals are shown for the combination chemotherapy regimens. The hazard ratio for a given comparison could be read in the intersection of two treatments. The strategies are grouped according to their baseline efficacy compared with observation-alone. All z-tests to compare two treatments were performed two-sided. * p < 0.05. Abbreviations: A = anthracycline; ATr = anthracycline-based triplet; C = cisplatin; E = etoposide; F = fluoropyrimidine; I = irinotecan; M = mitomycin C; Obs = observation; Ox = oxaliplatin; OxFpr = eight cycles of oxaliplatin-fluoropyrimidine thereafter eight cycles of fluoropyrimidine monotherapy; RCh = chemoradiotherapy; T = Taxane.